Hookipa Pharma Inc

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its product includes VaxWace and TheraT. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, Katherine Cohen, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended September 30, 2020 and provides a corporate update.

HOOKIPA Pharma Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

NEW YORK and VIENNA, Austria, Nov. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release financial results for the third quarter ended September 30, 2020 before the market opens on Thursday, November 12, 2020.

HOOKIPA Pharma To Report Third Quarter 2020 Financial Results on November 12, 2020

Peer reviewed article in OncoImmunology demonstrates promising preclinical results for the novel cancer therapy targeting Human Papillomavirus 16 (HPV16) E6/E7 

HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article

NEW YORK and VIENNA, Austria, Sept.  16, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at SVB Leerink’s CybeRx Series: Vaccine Forum, taking place September 23 – 24, 2020:

HOOKIPA Pharma to Present at SVB Leerink’s CybeRx Series Vaccine Forum

NEW YORK and VIENNA, Austria, Sept.  09, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in the following virtual investor conferences in September:

HOOKIPA Pharma to Present at Upcoming Conferences in September

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 39.13% and 138.32%, respectively, for the quarter ended June 2020.

HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Tops Revenue Estimates

NEW YORK and VIENNA, Austria, Aug.  13, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reports its financial results for the second quarter ended June 30, 2020 and provides a corporate update.

HOOKIPA Pharma Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

HOOKIPA Pharma Inc. (HOOK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NEW YORK and VIENNA, Austria, Aug.  04, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it will release financial results for the second quarter ended June 30, 2020 before the market opens on Thursday, August 13, 2020.

HOOKIPA Pharma To Report Second Quarter 2020 Financial Results on August 13, 2020

HOOKIPA Pharma Inc. (HOOK) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

NEW YORK and VIENNA, Austria, Aug.  03, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers, today announced that both the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have issued patents covering HOOKIPA’s proprietary replicating arenavirus technology (TheraT®).

HOOKIPA Announces Issuance of US and European Patents

NEW YORK and VIENNA, Austria, June  22, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced positive interim results on its prophylactic Cytomegalovirus (CMV) vaccine candidate HB‑101. HB‑101 is being investigated in a double-blind Phase 2 clinical trial (NCT03629080) to assess safety, immunogenicity and efficacy in patients receiving a kidney transplant from a live donor. HOOKIPA reported interim data on the trial’s primary endpoints, safety and B cell and T cell immunogenicity.

HOOKIPA Announces Positive Phase 2 Interim Safety and Immunogenicity Results for its CMV Vaccine Candidate HB‑101

NEW YORK and VIENNA, Austria, June  19, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that Dr. Sander van Deventer has resigned as a Non-Executive Director of the Company’s Board of Directors and Audit Committee.

HOOKIPA Announces Changes to its Board of Directors – Resignation of Sander van Deventer

NEW YORK and VIENNA, Austria, June  17, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for HB-202. This IND allows HOOKIPA to initiate an additional arm in its Phase 1/2 clinical trial for HB-201 (NCT04180215) for the treatment of Human Papillomavirus 16-positive (HPV 16+) cancers. With the IND clearance of HB-202, HOOKIPA will be able to examine not only the safety and efficacy of HB-201 alone but also HB-201 in combination with HB-202 as an alternating two-vector therapy.

HOOKIPA Announces FDA Clearance of its IND Application for HB-202/201 Clinical Trial to Treat HPV-Positive Cancers

HOOKIPA (HOOK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why HOOKIPA (HOOK) Stock Might be a Great Pick

HOOKIPA Pharma Inc (HOOK) delivered earnings and revenue surprises of -10.26% and -15.13%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc (HOOK) Reports Q1 Loss, Misses Revenue Estimates

NEW YORK and VIENNA, Austria, May  14, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reports its financial results and corporate update for the first quarter ended March 31, 2020.

HOOKIPA Pharma Reports First Quarter 2020 Financial Results and Provides a Corporate Update

HOOKIPA Pharma Inc (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will HOOKIPA Pharma Inc (HOOK) Report Negative Earnings Next Week? What You Should Know

HOOKIPA Pharma Inc.	 (HOOK) CEO Joern Aldag on Q4 2019 Results - Earnings Call Transcript

Viking Therapeutics

HOOKIPA Pharma and Viking Therapeutics could catch first at some point this year. Here's why.

2 Small-Cap Biotech Stocks to Watch in 2020

NEW YORK and VIENNA, Austria, Jan.  06, 2020  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA has made strong progress in its collaboration with Gilead for novel arenavirus-based therapeutics intended to support functional cures for chronic Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.

HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry

NEW YORK and VIENNA, Austria, Dec.  30, 2019  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that the first patient has been dosed in a Phase 1/2 clinical trial (NCT04180215) of HB-201, an immunotherapy for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers. This trial is HOOKIPA’s first clinical trial in immuno-oncology.

HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-201 for the Treatment of Human Papillomavirus 16-Positive Cancers

Hookipa's Technology Appears To Be A Vaccine Gamechanger Against Infectious Disease And Cancer

Christine D. Baker has joined as Chief Business Officer   Roman Necina, PhD, will join as Chief Technology Officer 

HOOKIPA Announces Key Hires to its Executive Team

NEW YORK and VIENNA, Austria, Sept.  19, 2019  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platforms, will present the anti-cancer impact of its TheraT® technology in four poster presentations at the CICON Cancer Immunotherapy Conference taking place September 25-28 in Paris. 

News for Hookipa Pharma Inc Stock (HOOK)